Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple SclerosisMult. Scler. 2020 Apr 30;[EPub Ahead of Print], E Fox, AE Lovett-Racke, M Gormley, Y Liu, M Petracca, S Cocozza, R Shubin, S Wray, MS Weiss, JA Bosco, SA Power, K Mok, M Inglese
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.